Last reviewed · How we verify
Satralizumab 120 mg
Satralizumab 120 mg, marketed by Hoffmann-La Roche, is a therapeutic agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence, supported by its current marketed status. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Satralizumab 120 mg |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD (PHASE4)
- Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) (PHASE2)
- A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Satralizumab 120 mg CI brief — competitive landscape report
- Satralizumab 120 mg updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI